BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2013 Financial Results on Tuesday, November 12, 2013
LYNBROOK, N.Y., Nov. 5, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, announced today that it will host a conference call and live audio webcast at 8:30 a.m. EST on Tuesday, November 12, 2013 to report its third quarter 2013 financial results and provide a corporate update.
In order to participate in the conference call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international). The live webcast can be accessed under "Events and Presentation" in the Investors section of the Company's website at www.biospecifics.com or you may use the link: http://www.videonewswire.com/event.asp?id=96458.
A replay of the call will be available one hour after the end of the conference on November 12, 2013 until 9:00 a.m. EST on November 23, 2013. To access the replay, please dial 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and reference the access code 10035642. The archived webcast will be available for 90 days in the Investors section of BioSpecifics' website at www.biospecifics.com.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is currently marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium), and Actelion has the marking rights in Canada. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set an action date for CCH for the additional indication of Peyronie's disease of December 6, 2013. CCH is marketed by Swedish Orphan Biovitrum AB as XIAPEX® (the EU tradename for CCH) for the treatment of Dupuytren's contracture in 71 Eurasian and African countries. CCH is in clinical development for the treatment of several additional promising indications. Auxilium is testing CCH for frozen shoulder syndrome and expects to initiate next stage trials in the fourth quarter of 2013. Auxillium is also testing CCH as a treatment for cellulite in a Phase 2a study. BioSpecifics is currently managing the development of CCH for the treatment of human and canine lipomas, both of which are in Phase 2 trials, and expects to report top-line data from these trials by the end of 2013. For more information, please visit www.biospecifics.com.
SOURCE BioSpecifics Technologies Corp.
More by this Source
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results
Mar 06, 2014, 08:00 ET
BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
Feb 19, 2014, 16:15 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.